TQ Therapeutics GmbH

TQ Therapeutics GmbH is pioneering a novel approach to cell and gene therapy with its TQx platform, which transforms the production of cellular therapies into a rapid, automated process that occurs at the patient's side. This method leverages extra-corporeal gene therapy while maintaining the benefits of autologous cell therapies, allowing for the creation of genetically modified immune cells like CAR-T cells. The approach eliminates the need for centralized production facilities, reducing time and costs, and making treatments more accessible. It addresses significant challenges of traditional autologous cell therapies, such as the individualized and time-consuming production process, by enabling immediate delivery and target cell specificity. This innovation opens possibilities for treating previously difficult conditions, including rare autoimmune diseases and cancers. The TQx process, supported by a team of experts in clinical development and operations, aims to revolutionize the cell and gene therapy landscape by making it widely available.